PGP Investors

In August 2002, PGP Corporation received $14 million in venture funding from DCM and Venrock Associates. In December 2005, PGP Corporation received an additional $10 million in growth capital from DCM, Venrock Associates, and SVB Capital. Funds are being used to accelerate R&D and continue expansion of the PGP “Deploy-Once” enterprise encryption platform.

DCM
DCM is an early-stage venture capital firm supporting entrepreneurs building world-class technology companies. The firm’s partners manage more than US$1.5 billion and have funded leading technology companies, including 2Wire, 51job (Nasdaq: JOBS), @Motion (Openwave), About.com (The New York Times Co.), All About (Jasdaq: 2454), Arroyo (Cisco), Dang Dang, Foundry Networks (Nasdaq: FDRY), HireRight, Internap (AMEX: IIP), IPivot (Intel), JCI (Nasdaq Japan - Hercules: 9424), Kabu.com (TSE Main:8703), PGP Corporation, Recourse Technologies (Symantec), Sigmatel (Nasdaq: SGTL), SMIC (NYSE: SMI), UUNet (MCI), and Vimicro (Nasdaq: VIMC). DCM offers hands-on operational guidance and access to an extensive network of resources, including close relationships with many of the Pacific Rim’s leading companies and investors. For more information, please visit DCM’s website at www.dcm.com.

Venrock Associates
Venrock is a premier venture capital firm with offices in Menlo Park, New York, Cambridge, MA, and Israel.  Originally established as the venture capital arm of the Rockefeller family, Venrock continues a seven-decade tradition of funding entrepreneurs and establishing successful, enduring companies.  Having invested $1.8 billion in 400 companies resulting in over 120 IPOs over the past 38 years, Venrock’s investment returns place it among the top tier venture capital firms that have achieved consistently superior performance.  With a primary focus on information technology, healthcare, and energy, portfolio companies have included Intel, Apple Computer, StrataCom, Check Point Software, and DoubleClick; Sirna Therapeutics, Centocor, Idec Pharmaceuticals, Sugen, Millennium Pharmaceuticals, and Illumina.  For more information, please visit Venrock’s website at  www.venrock.com.